Therapeutic modulation of transcription factor activity.

Emery, J G; Ohlstein, E H; Jaye, M

Emery, J G; Ohlstein, E H; Jaye, M.

Afiliación

Emery JG; Dept of Musculoskeletal Diseases, GlaxoSmithKline Pharmaceuticals, UW2109, King of Prussia, PA 19406-0939, USA.

Trends Pharmacol Sci ; 22(5): 233-40, 2001 May.

Article en En | MEDLINE | ID: mdl-11339974

RESUMEN

Aberrant gene expression is a fundamental cause of many disease-associated pathophysiologies. The pharmacological modulation of transcription factor activity therefore represents an attractive therapeutic approach to such disorders. With the exception of nuclear receptors, which are the direct targets of pharmaceuticals, other known classes of transcription factors are largely regulated indirectly by drugs that impact upon those signal transduction cascades that alter transcription factor phosphorylation and dephosphorylation and/or nuclear import. However, recent advances in drug discovery technologies now enable high-throughput screens that can identify molecules that act directly at the level of transcription factor complexes.

Asunto(s)

Regulación de la Expresión Génica/efectos de los fármacos; Factores de Transcripción/efectos de los fármacos; Animales; Regulación de la Expresión Génica/genética; Humanos; Factores de Transcripción/química; Factores de Transcripción/genética

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factores de Transcripción / Regulación de la Expresión Génica Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Trends Pharmacol Sci Año: 2001 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links